Fierce Biotech April 22, 2024
Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could benefit from its “neuroscience expertise in movement disorders.”
Skyhawk is, based on financing, deals and pipeline progress, at the forefront of efforts to expand the universe of druggable proteins by using small molecules to target RNA. Faced with undruggable targets, Skyhawk and peers such as Arrakis Therapeutics and Remix Therapeutics are betting they can alter levels of disease-driving proteins by hitting RNA upstream. Skyhawk has landed deals with Genentech, Merck & Co., Vertex and a who’s who of other leading drug developers on the strength of its platform.
Ipsen is the latest addition to Skyhawk’s star-studded list...
Today's Sponsors
Today's Sponsor